Want to join the conversation?
$MRK and $PFE announced treatment of first patient in Phase 3 study of avelumab, investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in an advanced renal cell carcinoma (RCC) setting. The study, JAVELIN Renal 101, is first pivotal trial investigating avelumab in combination with INLYTA (axitinib), tyrosine kinase inhibitor (TKI).
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.